# US 2024/0368109 A1 · Allosteric modulators of nicotinic acetylcholine receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0368109 A1
- Document ID: US20240368109A1
- Status: Published application
- Kind: A1
- Application number: 18/689,148
- Filed: 2022-09-19
- Published: 2024-11-07
- Earliest claimed: 2021-09-21
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme LLC
- Inventors: Ian M. Bell; Brendan M. Crowley; James Fells; Patrick Bazzini; Jean-Marie Contreras; Fabrice Garrido; Belinda C. Huff; Christophe Joseph; Christophe Morice; Dharam Paul; Aurelie Witzel
- Web page: https://patentgrep.com/patent/US20240368109A1

## CPC

- C07D 311/94: condensed with rings other than six-membered or with ring systems containing such rings
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/381: having five-membered rings
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4245: Oxadiazoles
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 233/60: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07D 209/94: containing carbocyclic rings other than six-membered
- C07D 213/56: Amides
- C07D 307/93: condensed with a ring other than six-membered
- C07D 311/74: Benzo[b]pyrans, hydrogenated in the carbocyclic ring
- C07D 333/78: condensed with rings other than six-membered or with ring systems containing such rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 491/048: the oxygen-containing ring being five-membered
- C07C 2603/08: containing three- or four-membered rings
- C07C 2603/12: only one five-membered ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present disclosure relates to compounds of formula I that are useful as modulators of α 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

## Claims

### Claim 1

A compound having the formula I
or a pharmaceutically acceptable salt thereof, wherein:
p is 1 or 2,
q is 0, 1 or 2,
each X is independently O, S, CRaRb, or NRc, provided that when p is 2 at least one X is CRaRb;
w is 0, 1, 2, 3 or 4;
Z is CRd or N;
each Ra and Rb is independently hydrogen, hydroxy, (C1-C4)alkoxy, halogen, cyano, (C1-C4)alkyl, or (C1-C4)haloalkyl;
Rc is hydrogen, (C1-C4)alkyl, (C1-C6)haloalkyl, S(O)2(C1-C4)alkyl, or —C═O(C1-C4)alkyl;
Rd is hydrogen, hydroxy, (C1-C4)alkoxy, halogen, cyano, (C1-C4)alkyl, or (C1-C4)haloalkyl;
each R5 is independently halogen, (C1-C4)alkyl, cyano, or (C1-C4)haloalkyl;
y is 0, 1, 2, or 3;
each R3 is independently selected from halogen, hydroxy, (C1-C6)alkyl, cyano, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, aryl, and heteroaryl, wherein said alkyl or alkoxy substituted with 0, 1, 2, 3, 4, or 5, and wherein said aryl or heteroaryl is substituted with 0, 1, 2, or 3 R6 substituents;
each R6 is independently (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C6)cycloalkyl, heterocycloalkyl, or aryl(C1-C6)alkyl, and wherein said alkyl or alkoxy is substituted with 0, 1, 2, 3, 4 or 5 fluoro;
R4 is hydrogen or (C1-C6)alkyl;
each R2 is hydrogen or (C1-C6)alkyl;
R1 is independently selected from hydrogen, (C1-C6)alkoxy, (C1-C6)haloalkyl, halogen, (C1-C6)heteroalkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkyl, (C3-C6)cycloalkyl, heterocycloalkyl, aryl, arylC1-6alkyl, —(C═O)OC1-4alkyl, and hydroxyC1-4alkyl;
each R1 and R together with the carbon atom to which they are attached may join together to form a ring, wherein said ring is substituted with 0, 1, 2, 3, or 4 substituents selected from: hydroxy, halogen, methoxy, CF3, and C1-6alkyl;
A is aryl, heteroaryl, heterocycloalkyl, or (C1-C5)cycloalkyl, wherein A is substituted with 0, 1, 2, 3, or 4 R7 substitutents;
each R7 is independently selected from hydrogen, halogen, hydroxy, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, aryl, heteroaryl, (C1-C6)alkyl, aryl(C1-C6)alkyl, (C3-C6)cycloalkyl(C1-C4)alkyl, (C3-C6)cycloalkyl(C1-C6)alkoxy, heterocycloalkyl, heterocycloalkyl(C1-C6)alkyl, and heteroaryloxy, wherein each R7 independently is substituted with 0, 1, 2, or 3 R8; and
each R8 is independently selected from halogen, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy, and (C1-C6)alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each X is independently CRaRb or NRc, provided that when p is 2 at least one X is CRaRb.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each X is independently O, S, or CRaRb, provided that when p is 2 at least one X is CRaRb.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Z is CRd.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Z is N.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each Ra and Rb is independently hydrogen, halogen, (C1-C4)alkyl, or (C1-C4)alkylcarbonyl.

### Claim 7 (depends on 6)

The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein each Ra and Rb is hydrogen.

### Claim 8 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein each R3 is independently selected from halogen, (C1-C6)alkyl, cyano, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, aryl, and heteroaryl, wherein said alkyl or alkoxy is optionally substituted with 1-5 fluoro, and wherein said aryl or heteroaryl is substituted with 0, 1, 2, or 3 R6 substituents.

### Claim 9 (depends on 8)

The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein each R3 is independently selected from methoxy, cyano, fluoro, chloro, bromo, tetrazolyl, triazolyl, isoxazolyl, and pyrimidyl, and wherein said heteroaryl is substituted with 0, 1, 2, or 3 R6 substituents.

### Claim 10 (depends on 9)

The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein A is selected from phenyl, naphthyl, indanyl, biphenyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, isoxazolyl, isoquinolinyl, naphthyridinyl, benzothienyl, benzofuranyl, benzothiazolyl, benzimidazole, benzpyrazolyl, indolyl, isoindolyl, indolizinyl, indazolyl, oxadiazolyl, purinyl, quinolizinyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzoxazolyl, benzisoxazolyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[2,3-b]pyridinyl, thieno[2,3-b]pyrrolyl, azetidinyl, chromanyl, 2,3-dihydrobenzofuranyl, 6,7-dihydro-5H-cyclopenta[b]pyridine, dioxolanyl, 5,6-dihydropyrrolo[1,2-b]pyrazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, 5,6,7,8-tetrahydroquinolinyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, hexahydroazepinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, oxazoline, isoxazoline, 1,4-dioxanyl, oxetanyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, tetrahydrothienyl, thiomorpholinyl, thiamorpholinyl, I-oxo-thiomorpholinyl, 1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazolyl, and 1,1-dioxothiomorpholinyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, wherein A is substituted with 0, 1, 2, or 3 R7 substitutents.

### Claim 11 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein A is selected from phenyl, hexyl, pyridyl, oxadiazolyl, chromanyl, 2,3-dihydrobenzofuranyl, indanyl, thienyl, benzofuranyl, isoxazolyl, and 1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazolyl, wherein A is substituted with 0, 1, 2, or 3 R7 substitutents.

### Claim 12 (depends on 11)

The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R7 is independently selected from ethoxy, hydrogen, methoxy, fluoro, phenyl, hydroxy, methyl, chloro, pyrrolidinyl, difluoromethyl, iodo, pyrrolyl, quinolinyl, benzothiazolyl, pyridyloxy, oxazolyl, bromo, cyclopropylmethyloxy, phenylmethyl, and pyridyl, wherein said aryl and heteroaryl are substituted with 0, 1, 2, or 3 R8.

### Claim 13 (depends on 12)

The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein each R1 is independently hydrogen, methoxymethyl, hydroxymethyl, trifluoromethyl, methoxy, difluoromethyl, fluoromethyl, methyl, ethyl, methlcarboxy, hydroxyethyl, or phenyl.

### Claim 14 (depends on 13)

The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein each R2 is independently hydrogen, methyl, ethyl, isopropyl, or propyl.

### Claim 15 (depends on 14)

The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein each R1 and R2 together with the carbon atom to which they are attached join together to form a ring, wherein said ring is substituted with 0, 1, or 2 hydroxy, halogen, methoxy, or C1-6alkyl.

### Claim 16 (depends on 1)

The compound of claim 1 which is selected from;
exo-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-1,1a,6,6a-tetrahydrocyclopropa[a]indene-1-carboxamide;
exo-N-[(1R)-1-cyclohexyl-2-hydroxyethyl]-6-fluoro-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-6-fluoro-N-[(1R)-2,2,2-trifluoro-1-(2-methoxypyridin-4-yl)ethyl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-5-(2H-tetrazol-5-yl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-(1-benzyl-1H-1,2,3-triazol-4-yl)-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[3-(4-fluorophenyl)oxetan-3-yl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-6-fluoro-N-[3-(4-fluorophenyl)oxetan-3-yl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(1R)-1-(6-ethoxypyridin-3-yl)-2-hydroxyethyl]-6-fluoro-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-(2-cyclohexyl-2-methoxyethyl)-6-fluoro-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[1-(4-fluorophenyl)-3-hydroxycyclobutyl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(1R)-1-cyclohexyl-2-hydroxyethyl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(1R)-1-cyclohexyl-2,2-difluoroethyl]-6-fluoro-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-6-fluoro-N-(1-phenylcyclobutyl)-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-6-fluoro-N-[1-(4-fluorophenyl)cyclopropyl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[1-(2-methoxypyridin-4-yl)cyclopropyl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[1-(6-ethoxypyridin-3-yl)cyclobutyl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[1-(2-methoxypyridin-4-yl)cyclobutyl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(1R)-1-(6-ethoxypyridin-3-yl)-2,2,2-trifluoroethyl]-6-fluoro-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(1R)-1-(6-ethoxypyridin-3-yl)-2,2-difluoroethyl]-6-fluoro-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(1R)-1-(6-ethoxypyridin-3-yl)-2-fluoroethyl]-6-fluoro-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-6-fluoro-N-[(1R)-2-fluoro-1-(2-methoxypyridin-4-yl)ethyl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(2,6-dimethoxyphenyl)methyl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[2-(3-chlorophenyl)propan-2-yl]-6-fluoro-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(4S)-6,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-yl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(1R)-1-cyclohexyl-2,2-difluoroethyl]-1,1a,2,7b-tetrahydrocyclopropa[c][1]benzopyran-1-carboxamide;
exo-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-3-chloro-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-3-bromo-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-(3,5-dimethyl-1,2-oxazol-4-yl)-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-5-(pyrimidin-5-yl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-2-acetyl-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-1,1a,2,6b-tetrahydrocyclopropa[b]indole-1-carboxamide;
exo-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-6-methoxy-1a,6b-dihydro-1H-cyclopropa[4,5]furo[3,2-c]pyridine-1-carboxamide;
exo-5-cyano-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-4-bromo-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-4-methoxy-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-6-bromo-N-[(1R)-1-(4-ethoxyphenyl)-2-methoxyethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(4R)-6-fluoro-3,4-dihydro-1H-2-benzopyran-4-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(1R)-1-cyclohexyl-2-hydroxyethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzothiophene-1-carboxamide;
exo-N-[1-(6-ethoxypyridin-3-yl)cyclobutyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(4R)-6,7-dimethoxy-3,4-dihydro-1H-2-benzopyran-4-yl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(1R)-1-(6-ethoxypyridin-3-yl)-2,2-difluoroethyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(4S)-7-fluoro-3,4-dihydro-2H-1-benzopyran-4-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(4S)-6,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-yl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-(6-methoxy-2,3-dihydro-1-benzofuran-3-yl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-(4-hydroxy-2,3-dihydro-1H-inden-1-yl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-(2-phenylethyl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide exo-5-fluoro-N-[1-(thiophen-2-yl)ethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
methyl 2-(3-fluorophenyl)-2-[(exo-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carbonyl)amino]acetate;
exo-N-[(5-chloro-2-fluorophenyl)methyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(4-chloro-3-fluorophenyl)methyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
2-{1-[(exo-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carbonyl)amino]propyl}pyridine;
exo-5-fluoro-N-[(thiophen-2-yl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
2-{[(exo-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carbonyl)amino]methyl}-6-(pyrrolidin-1-yl)pyridine;
exo-N-{[2,6-bis(difluoromethyl)pyridin-4-yl]methyl}-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[1-(1-benzofuran-2-yl)ethyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(3-iodophenyl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(2,5-difluorophenyl)methyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(2,4-difluorophenyl)methyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(3-fluoro-5-methylphenyl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-{[4-(1H-pyrrol-1-yl)phenyl]methyl}-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(4-hydroxyphenyl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
6-{[(exo-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carbonyl)amino]methyl}quinoline;
2-{[(exo-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carbonyl)amino]methyl}-1,3-benzothiazole;
methyl 2-(3-chlorophenyl)-2-[(exo-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carbonyl)amino]acetate;
exo-5-fluoro-N-[(1S)-1-(4-fluorophenyl)-3-hydroxypropyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(2-methylphenyl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(3-phenyl-1,2-oxazol-5-yl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
3-{[(exo-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carbonyl)amino]methyl}-1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole;
exo-5-fluoro-N-({4-[(pyridin-2-yl)oxy]phenyl}methyl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-{[3-(1,3-oxazol-2-yl)phenyl]methyl}-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
5-{(1S)-1-[(exo-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carbonyl)amino]ethyl}quinoline;
exo-N-[1-(4-bromophenyl)ethyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
6-{[(exo-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carbonyl)amino]methyl}isoquinoline;
4-{[(exo-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carbonyl)amino](phenyl)methyl}pyridine;
exo-N-{[2-(cyclopropylmethoxy)phenyl]methyl}-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(3-bromo-1,2,4-oxadiazol-5-yl)methyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(3-benzyl-1,2,4-oxadiazol-5-yl)methyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[1-(1,2-oxazol-5-yl)ethyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-{[3-(4-methoxyphenyl)-1,2-oxazol-5-yl]methyl}-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(3-methoxy-1,2-oxazol-5-yl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-{[3-(pyridin-2-yl)-1,2-oxazol-5-yl]methyl}-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-N-[(3-bromo-1,2-oxazol-5-yl)methyl]-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(3-phenyl-1,2-oxazol-5-yl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
exo-5-fluoro-N-{[3-(6-methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl]methyl}-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide; and
exo-N-{[3-(4-chlorophenyl)-1,2-oxazol-5-yl]methyl}-5-fluoro-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-carboxamide;
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, further comprising a second therapeutic agent selected from the group consisting of acetylcholinesterase inhibitors; NMDA receptor antagonists; antipsychotics; MAO-B inhibitors; and levodopa.

### Claim at position 19

-21. (canceled)

### Claim 22 (depends on 1)

A method of treating a patient with cognitive impairments associated with Alzheimer's disease, Parkinson's disease, and schizophrenia, the method comprising administering to the patient the compound of claim 1, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the patient.
